Technical Analysis for XCUR - Exicure, Inc.

Grade Last Price % Change Price Change
grade D 2.758 6.08% 0.16
XCUR closed up 5.69 percent on Tuesday, November 19, 2019, on 52 percent of normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical XCUR trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 6.08%
50 DMA Resistance Bearish 6.08%
Crossed Above 20 DMA Bullish 6.08%
Calm After Storm Range Contraction 12.11%
Doji - Bullish? Reversal 12.11%
Fell Below 200 DMA Bearish 11.66%
Fell Below 20 DMA Bearish 11.66%
Fell Below 50 DMA Bearish 11.66%
MACD Bearish Signal Line Cross Bearish 11.66%
Crossed Above 200 DMA Bullish 0.66%

Older signals for XCUR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Exicure, Inc., a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005; and license and development agreement DERMELIX, LLC, d/b/a Dermelix Biotherapeutics to research, develop, and commercialize Exicure's technology for the treatment of Netherton Syndrome and for five additional rare skin indications. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.
Biotechnology Biopharmaceutical Life Sciences Psoriasis Seattle Genetics Netherton Syndrome Purdue Pharma
Is XCUR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.2
52 Week Low 1.62
Average Volume 322,657
200-Day Moving Average 2.628
50-Day Moving Average 2.605
20-Day Moving Average 2.57
10-Day Moving Average 2.53
Average True Range 0.2271
ADX 23.27
+DI 29.1676
-DI 19.7145
Chandelier Exit (Long, 3 ATRs ) 2.5187
Chandelier Exit (Short, 3 ATRs ) 3.0113
Upper Bollinger Band 2.7752
Lower Bollinger Band 2.3648
Percent B (%b) 0.57
BandWidth 15.968872
MACD Line -0.0167
MACD Signal Line -0.0151
MACD Histogram -0.0016
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.08
Resistance 3 (R3) 3.07 2.91 3.00
Resistance 2 (R2) 2.91 2.78 2.91 2.97
Resistance 1 (R1) 2.75 2.71 2.83 2.76 2.95
Pivot Point 2.59 2.59 2.63 2.59 2.59
Support 1 (S1) 2.43 2.46 2.51 2.44 2.25
Support 2 (S2) 2.27 2.39 2.27 2.23
Support 3 (S3) 2.11 2.27 2.20
Support 4 (S4) 2.12